Medical science liaisons (MSLs) play an essential and prominent role in the pharmaceutical industry. To support the various market changes, the scope of the average MSL function will expand. This article explores the evolving role of MSLs and their value for biopharmaceutical companies, and examines how best to utilize their expertise.
If you are not happy with the results below please do another search
50 search results for:
Funding initiatives this week saw money flow into cancer, rare liver diseases, respiratory depression, chemotherapy-related toxicities and a cutting-edge machine learning platform, while a biotech start-up guns for an IPO.
Pheon Therapeutics launched with $63 million in Series A financing and a vision of ushering in the next generation of antibody-drug conjugates.
TCR2 Therapeutics announced promising Phase I data for gavo-cel in mesothelin-expression that points toward effects in multiple solid tumors, especially ovarian cancer.
Today’s promising results from Eisai and Biogen’s Alzheimer’s drug trial have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly.
Johnson & Johnson named its consumer business Kenvue on Wednesday, moving ahead with its plans to spin-off the unit in what would be the biggest shake-up in the healthcare conglomerate’s 135-year history.
An experimental Alzheimer’s drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.
As a result of surging electricity costs, Europe’s drugmakers have warned they may stop making some cheap generic medicines and are calling for an overhaul of the way they are priced. The industry is just the latest to seek help as the energy crisis deepens.
The committee will reveal in a Wednesday report that after adapting a method used by CDC scientists and adjusting for inflation, it found that the crisis cost the U.S. economy $1.47 trillion in 2020, a $487 billion increase from 2019.
With a range of heavy-hitting speakers, including former President Barack Obama, attendees gathered at the Brooklyn Navy Yard to learn more about the possibilities of the future of healthcare and biomedicine, and reflect on lessons learned from the past.